Evidence map›Paper›PMID 33224694›Full record

ArticleThe mental health clinician2020

Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders.

Amy Werremeyer, Jolene Bostwick, Carla Cobb, Tera D Moore, Susie H Park, Cristofer Price, Jerry McKee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The mental health clinician, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amy WerremeyerAssociate Professor, School of Pharmacy, North Dakota State University, Fargo, North Dakota, amy.werremeyer@ndsu.edu.ORCID https://orcid.org/0000-0002-7933-4980
Jolene BostwickClinical Professor and Associate Chair, University of Michigan College of Pharmacy, Ann Arbor, Michigan.ORCID https://orcid.org/0000-0003-4587-7773
Carla CobbOwner and Consultant, Capita Consulting, Billings, Montana.ORCID https://orcid.org/0000-0002-0827-5485
Tera D MooreNational Pharmacy Benefits Management Program Manager, Clinical Practice Integration and Model Advancement, Clinical Pharmacy Practice Office, Pharmacy Benefits Management Services, US Department of Veterans Affairs, Washington, DC.ORCID https://orcid.org/0000-0002-9781-6545
Susie H ParkAssociate Professor, School of Pharmacy, University of Southern California, Los Angeles, California.ORCID https://orcid.org/0000-0003-2402-822X
Cristofer PriceClinical Pharmacy Program Manager - Mental Health, Providence Veterans Affairs Medical Center, Providence, Rhode Island.ORCID https://orcid.org/0000-0002-5412-5840
Jerry McKeeCEO and Lead Consultant, Psychopharm Solutions LLC, Morganton, North Carolina.ORCID https://orcid.org/0000-0002-5721-0338

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPsychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. A 2015 review highlighted the value of psychiatric pharmacists in improving medication-related outcomes. There is a need to describe areas of expansion and strengthened evidence regarding pharmacist practice and patient care impact in psychiatric and neurologic settings since 2015.

methodsA systematic search of literature published from January 2014 to June 2019 was conducted. Publications describing patient-level outcome results associated with pharmacist provision of care in a psychiatric/neurologic setting and/or in relation to central nervous system (CNS) medications were included.

resultsA total of 64 publications were included. There was significant heterogeneity of published study methods and data, prohibiting meta-analysis. Pharmacists practicing across a wide variety of health care settings with focus on CNS medication management significantly improved patient-level outcomes, such as medication adherence, disease control, and avoidance of hospitalization. The most common practice approach associated with significant improvement in patient-level outcomes was incorporation of psychiatric pharmacist input into the interprofessional health care team. DISCUSSION: Pharmacists who focus on psychiatric and neurologic disease improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Additional studies designed to measure pharmacists' impact on patient-level outcomes are encouraged to strengthen these findings.

Indexed as

interprofessional teammedication managementneurologic pharmacistpatient-level outcomespsychiatric pharmacist

Identifiers

PMID33224694
PMCPMC7653731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.